Glucotrack's Participation in ADCES Annual Meeting
Glucotrack, Inc. (NASDAQ: GCTK), a pioneering medical device firm specializing in diabetes care, is set to participate in the highly anticipated Association of Diabetes Care and Education Specialists (ADCES) Annual Meeting. This event is scheduled to take place in Phoenix, Arizona, from August 8-11, 2025. Glucotrack is preparing to unveil significant advancements, including the commencement of a long-term early feasibility study following successful results from initial clinical trials.
What to Expect from the Conference
The ADCES Annual Meeting serves as a crucial platform where top experts in diabetes care come together to discuss the latest developments and insights in diabetes management and education. This year, Glucotrack will be presenting its innovative Continuous Blood Glucose Monitor (CBGM) at Booth #1724 in the Exhibit Hall. The company is also set to present a clinical poster focusing on physician opinions about continuous blood glucose monitoring technology.
Details of the Scientific Poster
Poster Title: Endocrinologists' Perspectives on an Implantable Continuous Blood Glucose Monitor
Session Date / Time: Saturday, August 9, 12:00 PM - 1:00 PM MST
Introducing the Continuous Blood Glucose Monitor
Paul V. Goode, PhD, President and CEO of Glucotrack, expressed enthusiasm about showcasing their CBGM at the ADCES meeting. He emphasized that this device is the next step in diabetes management, providing patients with a fully implantable solution that delivers real-time and precise glucose readings without the need for traditional wearables. This conference represents a prime opportunity to engage with leading figures in diabetes care about the advancements in blood glucose monitoring.
About the CBGM Technology
Unlike conventional continuous glucose monitors (CGM), which measure glucose through the skin and interstitial fluid, Glucotrack’s CBGM offers a revolutionary approach. It operates from within the body, obtaining blood glucose levels directly from blood samples, thus eliminating the use of cumbersome on-body devices. The implantable nature of this technology allows the sensor to function effectively for up to three years, significantly reducing interruptions for those managing diabetes.
Future Goals and Commitment
Glucotrack remains committed to enhancing the lives of diabetes patients through innovative technology. Their continuous blood glucose monitoring system is currently under development, focusing on long-term reliability, minimal calibration, and the elimination of on-body components. As they advance through clinical trials, Glucotrack aims to redefine diabetes management by addressing the pivotal limitations of existing CGM technologies.
Contact Information for Inquiries
If you wish to learn more about Glucotrack’s innovative CBGM, feel free to reach out through their official channels:
Investor Relations:
investors@glucotrack.com
Media Inquiries:
GlucotrackPR@icrinc.com
Frequently Asked Questions
What is the main innovation Glucotrack will present?
Glucotrack will showcase its Continuous Blood Glucose Monitor, which offers an implantable solution for real-time glucose monitoring.
Where will Glucotrack exhibit its technology?
They will exhibit at Booth #1724 during the ADCES Annual Meeting held in Phoenix, Arizona.
What is the duration of the CBGM's functionality?
The CBGM is designed to last for up to three years, minimizing the need for frequent sensor changes.
What key topics will Glucotrack discuss at the conference?
The company will discuss broader implications of blood-based continuous glucose monitoring and present findings from their clinical studies.
How can patients benefit from Glucotrack's technology?
The CBGM aims to significantly improve glucose monitoring accuracy and ease for diabetes patients, enhancing their overall quality of life.
